|
Getting personal with myelodysplastic syndromes: is now the right time? |
Apr 2019 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
Sep 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
Mar 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
|
Novel therapeutic choices in immune aplastic anemia |
Sep 2020 |
F1000Research |
Aplastic Anemia |
|
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
May 2023 |
Frontiers in Oncology |
Aplastic Anemia |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
Jan 2021 |
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
|
Is blood transfusion safe during the COVID-19 pandemic? |
Sep 2020 |
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions |
May 2020 |
Haematologica |
Aplastic Anemia |
